Acorda Therapeutics, Inc.
ACORNASDAQHealthcare
$0.66
$-0.21(-24.02%)
Market Cap$821028
P/E Ratio—
52W High$24.2
52W Low$0.6116
Acorda Therapeutics, Inc. (ACOR) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ACOR · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2023-12 | 2022-12 | 2021-12 | 2020-12 | 2019-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.12B | $0.12B | $0.13B | $0.15B | $0.19B |
| Cost of Revenue | $0.05B | $0.03B | $0.04B | $0.03B | $0.03B |
| Gross Profit | $0.07B | $0.09B | $0.09B | $0.12B | $0.16B |
| Gross Margin %(computed) | 60.86% | 74.42% | 68.40% | 78.09% | 81.89% |
| Operating Expenses | |||||
| R&D Expenses | $0.01B | $0.01B | $0.01B | $0.02B | $0.06B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $0.09B | $0.13B | $0.17B | $0.21B | $0.28B |
| Operating Income | ($0.02B) | ($0.04B) | ($0.08B) | ($0.09B) | $0.01B |
| Operating Margin %(computed) | -19.78% | -35.45% | -59.89% | -56.81% | 7.56% |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.03B | $0.03B | $0.03B | $0.03B | $0.02B |
| Income Before Tax | ($0.30B) | ($0.04B) | ($0.11B) | ($0.11B) | ($0.27B) |
| Income Tax Expense | ($0.04B) | $0.03B | ($0.01B) | ($0.01B) | ($0.00B) |
| Net Income | ($0.25B) | ($0.07B) | ($0.10B) | ($0.10B) | ($0.27B) |
| Net Margin %(computed) | -214.95% | -55.59% | -80.54% | -65.11% | -141.87% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-203.59 | $-66.90 | $-195.75 | $-246.40 | $-689.42 |
| Wtd Avg Shares | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B |
| EBITDA | ($0.20B) | ($0.01B) | ($0.04B) | ($0.06B) | $0.04B |
| EBITDA Margin %(computed) | -171.57% | -8.46% | -34.71% | -42.46% | 20.88% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · B
Explore more Acorda Therapeutics, Inc. data
About Acorda Therapeutics, Inc. (ACOR) Income Statement
Acorda Therapeutics, Inc. (ACOR) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2023, ACOR reported revenue of $0.12B, gross profit of $0.07B (gross margin 60.86%), and net income of ($0.25B) — a net profit margin of -214.95%.
Frequently asked questions
ACOR · 4 questionsAcorda Therapeutics, Inc. (ACOR) reported revenue of $0.12B for 2023, down 0.8% year-over-year.
ACOR revenueACOR salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09